WOOJUNG BIO Proposes Name Change to Kolmar BioTech, Business Diversification, and Appointment of Inside Director
WOOJUNG BIO will hold an extraordinary general meeting on July 8, 2026, to change its corporate name to Kolmar BioTech Inc. and amend its articles of incorporation to add business purposes including animal pharmaceuticals, feed, and health functional foods.
The meeting also proposes the appointment of Ham Seok-hee as an inside director. Major shareholders holding approximately 33.61% or 5,657,027 shares have delegated their voting rights to Kolmar Holdings.
An amendment to executive retirement pay regulations is also on the agenda. This shareholder meeting marks a governance restructuring toward integration with the Kolmar Group and business expansion.
[AI Summary]This extraordinary general meeting focuses on governance improvements and business diversification without capital changes. While short-term stock price impact is limited, mid-to-long-term growth drivers from Kolmar Group synergy are anticipated.